Lipid-lowering therapy and long-term survival in heart transplantation.
The influence of lipid-lowering therapy employing a historic cohort study design was assessed following heart transplantation. Lipid-lowering therapy appears to confer a survival benefit in cardiac transplant recipients who survive beyond the first year.
Stapleton
D D
DD
Department of Internal Medicine, Ochsner Medical Institutions, New Orleans, Louisiana 70121, USA.
Mehra
M R
MR
Dumas
D
D
Smart
F W
FW
Milani
R V
RV
Lavie
C J
CJ
Ventura
H O
HO
D000328:Adult; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D016027:Heart Transplantation / Q000401:mortality*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol; D015248:Gemfibrozil